Drug Type Small molecule drug |
Synonyms fostrox, Fostroxacitabine Bralpamide Hydrochloride, MIV 818 + [2] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H30BrN4O8P |
InChIKeyJBYKMODFCUCTGY-LLSQRQBFSA-N |
CAS Registry2129993-56-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrolamellar Hepatocellular Carcinoma | Phase 2 | United States | 05 Sep 2018 | |
Fibrolamellar Hepatocellular Carcinoma | Phase 2 | Belgium | 05 Sep 2018 | |
Fibrolamellar Hepatocellular Carcinoma | Phase 2 | Spain | 05 Sep 2018 | |
Fibrolamellar Hepatocellular Carcinoma | Phase 2 | United Kingdom | 05 Sep 2018 | |
Intrahepatic Cholangiocarcinoma | Phase 2 | United States | 05 Sep 2018 | |
Intrahepatic Cholangiocarcinoma | Phase 2 | Belgium | 05 Sep 2018 | |
Intrahepatic Cholangiocarcinoma | Phase 2 | Spain | 05 Sep 2018 | |
Intrahepatic Cholangiocarcinoma | Phase 2 | United Kingdom | 05 Sep 2018 | |
Liver metastases | Phase 2 | United States | 05 Sep 2018 | |
Liver metastases | Phase 2 | Belgium | 05 Sep 2018 |
Phase 1/2 | Liver Cancer Second line | Third line | - | gpnprpmxzm(pfjgulcjrx) = hvmpwazkcn izxhlenzur (ngbknusjbs, 7.6 – NR) View more | Positive | 20 Feb 2025 | ||
NCT03781934 (ESMO2024) Manual | Phase 1/2 | 21 | laerwsvtvv(sjupwfjbvx) = whazacxwer onyrbjfoib (nxdflmknbl ) View more | Positive | 16 Sep 2024 | ||
PRNewswire Manual | Phase 1/2 | Liver Cancer Second line | - | sendakguwi(nsdbmghmoa) = caknikptfq xlbvkwuhwa (sryvgixgra ) View more | Positive | 27 Jun 2024 | |
Phase 1/2 | Advanced Hepatocellular Carcinoma Second line | Third line | 21 | ecteictljt(qkofmucrec) = The safety profile was consistent with each individual agent. Consistent with the tumor selective DNA-damage, no major negative impact on liver function tests were observed during treatment. tftwmcjhyo (fgcvadujkq ) | Positive | 27 Jun 2024 | ||
Phase 1/2 | 18 | fmwxbfqrkw(xbxupaxpfg) = wilvtijkrd brffuzxzvh (mfwmypvozl ) View more | Positive | 18 Jan 2024 | |||
NCT03781934 (PRNewswire) Manual | Phase 1/2 | - | ikqdfczrri(otrwkqkwjc) = nelbxwfkzb tigsctpkma (vmqjtkwrvq ) View more | Positive | 19 Dec 2023 | ||
Phase 2 | 20 | ocjufmlbns(cyicfcezdl) = The combination remains tolerable with no unexpected new safety events and adverse events are transient and manageable. hnfpiybfxm (ulqfprlekv ) | Positive | 05 Oct 2023 | |||
Phase 1/2 | 6 | rcsdgdyvuh(llvepnilhe) = mimbmigcrr axtaesctpc (ulabvgvcyr ) View more | Positive | 04 Sep 2023 | |||
Phase 1/2 | - | cnsxbzdilh(zpadjrqrqt) = xncucqitnh vxdaesrulc (guglpnsdjw ) | - | 03 Feb 2022 | |||
Phase 1 | 9 | fncqcaueyh(orfqjyvmqb) = The most common treatment emergent AEs were those in the haematological system; raised LFTs and pruritus were also commonly reported. dhpwhaxmfx (zebnhfuhzd ) View more | Positive | 16 Sep 2021 |